Editorial: Diabetes and bone - from cell to human

Editorial: Diabetes and bone - from cell to human

Bibliographic Details
Main Authors:	Peter Vestergaard, Antonino Catalano, Jakob Starup-Linde
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Endocrinology
Subjects:	bone diabetes fractures alendronate antidiabetics medication
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1085953/full

Similar Items

The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study
by: Rikke Viggers, et al.
Published: (2022-01-01)

Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
by: Rikke Viggers, et al.
Published: (2021-11-01)

Skeletal Fragility in Type 2 Diabetes Mellitus
by: Jakob Starup-Linde, et al.
Published: (2018-09-01)

Diabetes, biochemical markers of bone turnover, diabetes control and bone
by: Jakob eStarup-Linde, et al.
Published: (2013-03-01)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-08-01)

Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes
by: Jakob Kau Starup-Linde, et al.
Published: (2021-03-01)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-10-01)

Type 1 Diabetes and Bone Fragility: Links and Risks
by: Starup-Linde J, et al.
Published: (2019-12-01)

The Effects of 12-Weeks Whey Protein Supplements on Markers of Bone Turnover in Adults With Abdominal Obesity – A Post Hoc Analysis
by: Rasmus Fuglsang-Nielsen, et al.
Published: (2022-03-01)

Diabetes and bone
by: Katrine Hygum, et al.
Published: (2019-06-01)

The Impact of Alendronate on Bone Mineral Density of Osteoporotic Patients
by: Hamidreza Aghaei-Meybodi, et al.
Published: (2013-12-01)

Review article: effects of type 2 diabetes therapies on bone metabolism
by: A. G. D. Vianna, et al.
Published: (2017-09-01)

Radiodensitometric and DXA analyses for the measurement of bone mineral density after systemic alendronate therapy
by: Marília Pacífico Lucisano, et al.
Published: (2013-06-01)

In vivo study of bovine hydroxyapatite-gelatin-hydroxypropyl methylcellulose with alendronate as injectable bone substitute composite in osteoporotic animal model
by: Aniek Setiya Budiatin, et al.
Published: (2022-01-01)

Morphological and histomorphometric evaluation of autogenous bone graft resorption in rabbits treated with alendronate sodium
by: Teo Mario da ROSA, et al.

Site-activatable targeting of macromolecular alendronate for accelerated fracture healing
by: Makoto Matsui, et al.
Published: (2023-12-01)

Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment
by: Chunlan Jing, et al.
Published: (2022-06-01)

Modern principles for the diagnosis and treatment of postmenopausal osteoporosis: a focus on bisphosphonates
by: I. B. Belyaeva, et al.
Published: (2020-08-01)

Bone healing study of alendronate combined with enoxaparin sodium bone cement in rabbits with bone defects
by: Zhihang Xiao, et al.
Published: (2022-09-01)

Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes
by: Cristiana Cipriani, et al.
Published: (2023-11-01)

Influence of bisphosphonates on alveolar bone density: a histomorphometric analysis
by: Milton Santamaria Júnior, et al.
Published: (2010-09-01)

Alendronate in patients with calcium nephrolithiasis and loss of bone mass
by: Arrabal-Polo Miguel, et al.
Published: (2012-08-01)

VIBE: Evaluation of Ibandronate Efficacy - Original Investigation
by: J-Y Reginster, et al.
Published: (2008-12-01)

Understanding the Protective Effect of Phytate in Bone Decalcification Related-Diseases
by: Pilar Sanchis, et al.
Published: (2021-08-01)

Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment
by: Jarusriwanna A, et al.
Published: (2024-02-01)

Inhibited Maternal Bone Resorption Suppress Fetal Rat Bone Development During Pregnancy
by: Huanhuan Jia, et al.
Published: (2020-02-01)

Bone-targeted methotrexate–alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo
by: Zi’ang Xie, et al.
Published: (2018-01-01)

The Findings of Bone Mineral Densitometry Following Preventive Treatment with Alendronate in Menopausal Women with Osteopenia; What is the Best Dose?
by: Mansour Karimifar, et al.
Published: (2020-12-01)

Comparison of the effect of alendronate and pamidronate on bone density of patients with osteoporosis
by: Zohre Nobakht, et al.
Published: (2018-12-01)

Experience with Alendronate Treatment for Four Years among Japanese Men with Osteoporosis or Osteopenia and Clinical Risk Factors for Fractures [Retraction]
by: Iwamoto J, et al.
Published: (2022-08-01)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
by: S. Akı, et al.
Published: (2002-03-01)

Bilateral Atypical Femoral Fractures after Bisphosphonate Treatment for Osteoporosis: A Literature Review
by: SeokJoon Hwang, et al.
Published: (2023-01-01)

Alendronate-Grafted Nanoemulsions for Bone-Targeted Vincristine Delivery: Preliminary Studies on Cell and Animal Models
by: Ian Stoppa, et al.
Published: (2024-02-01)

Effects of Alendronate and Raloxifene on Bone Density and Bone Turnover Markers in Postmenopausal Women
by: Ebru Zülfikaroğlu, et al.
Published: (2011-04-01)

Osteolytic Bone Loss and Skeletal Deformities in a Mouse Model for Early-Onset Paget’s Disease of Bone with <i>PFN1</i> Mutation Are Treatable by Alendronate
by: Zhu Ling, et al.
Published: (2023-10-01)

Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis
by: Elma Kučukalić-Selimović, et al.
Published: (2011-02-01)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
by: Fatemeh Khanizadeh, et al.

The Risk Factors of Severe Hypoglycemia in Older Patients with Dementia and Type 2 Diabetes Mellitus
by: Nai-Ching Chen, et al.
Published: (2022-01-01)

Short term sodium alendronate administration improves the peri-implant bone quality in osteoporotic animals
by: Danila de OLIVEIRA, et al.

Alendronato administrado en el foco de fractura. Estudio experimental en conejos. [Alendronate administered at the fracture site. Experimental study in rabbits].
by: Javier Eduardo Nuñez, et al.
Published: (2017-11-01)